(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
07 April 2022 (07.04.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/072888 A1

(51) International Patent Classification:
A61K 35/76 (2015.01) *A61K 38/48* (2006.01)
A61K 38/17 (2006.01) *A61K 39/395* (2006.01)
A61K 38/46 (2006.01)

(21) International Application Number:
PCT/US2021/053245

(22) International Filing Date:
01 October 2021 (01.10.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/086,165 01 October 2020 (01.10.2020) US

(71) Applicant: **SANGAMO THERAPEUTICS, INC.** [US/US]; 7000 Marina Blvd., Brisbane, California 94005 (US).

(72) Inventors: **HU, Jing**; c/o Sangamo Therapeutics, Inc., 7000 Marina Blvd., Brisbane, California 94005 (US). **LU, Yanmei**; c/o Sangamo Therapeutics, Inc., 7000 Marina Blvd., Brisbane, California 94005 (US).

(74) Agent: **MANGASARIAN, Karen** et al.; Haley Guiliano LLP, 75 Broad Street, Suite 1000, New York, New York 10004 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*

(54) Title: METHODS OF DETECTING ANTI-AAV ANTIBODIES

(57) Abstract: The disclosure relates to total antibody assays, including screening assays and confirmatory assays, for the detection of anti-AAV (e.g. anti-AAV6) antibodies in a subject as it relates to pre- and post-treatment total antibody levels. The disclosure also relates to methods of treating a subject with a gene therapy comprising a rAAV (e.g. rAAV6) vector.

Figure 8



WO 2022/072888 A1